Preserves access to affordable drugs

Summary

The bill adds a new section to New York’s public health law that treats settlement agreements between brand‑name drug owners and generic or biosimilar makers as unlawful when the generic company receives a benefit and agrees to stop developing or selling its product. It aims to stop deals that keep lower‑cost drugs off the market, while allowing limited settlements that only grant early marketing rights or modest litigation‑cost reimbursements. The purpose is to keep affordable medicines available to New Yorkers.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share